Zacks: Asterias Biotherapeutics Inc (AST) Receives Average Recommendation of “Strong Buy” from Analysts
Shares of Asterias Biotherapeutics Inc (NYSE:AST) have been assigned a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokers have set a twelve-month consensus price objective of $8.88 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given Asterias Biotherapeutics an industry rank of 99 out of 265 based on the ratings given to related companies.
AST has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Monday, July 17th. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Monday, June 12th.
Several hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its stake in Asterias Biotherapeutics by 24.1% in the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 63,773 shares during the last quarter. Teachers Advisors LLC increased its stake in Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after buying an additional 6,714 shares during the last quarter. Family Management Corp increased its stake in Asterias Biotherapeutics by 15.6% in the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock worth $168,000 after buying an additional 6,416 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Asterias Biotherapeutics by 4.6% in the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,100 shares during the last quarter.
Asterias Biotherapeutics (AST) traded up 2.239% during trading on Friday, hitting $3.425. The company’s stock had a trading volume of 47,109 shares. Asterias Biotherapeutics has a one year low of $2.54 and a one year high of $5.80. The company has a 50-day moving average of $3.37 and a 200 day moving average of $3.38. The firm’s market cap is $171.17 million.
Asterias Biotherapeutics (NYSE:AST) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). The company had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million. Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. On average, equities analysts forecast that Asterias Biotherapeutics will post ($0.61) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-asterias-biotherapeutics-inc-ast-receives-average-recommendation-of-strong-buy-from-analysts/1530175.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.